Synthetically defined glycoprotein vaccines: current status and future directions.
about
Protection against Experimental Melioidosis with a Synthetic manno-Heptopyranose Hexasaccharide GlycoconjugateMonitoring antigenic protein integrity during glycoconjugate vaccine synthesis using capillary electrophoresis-mass spectrometryFrom Immunologically Archaic to Neoteric Glycovaccines.Defined conjugation of glycans to the lysines of CRM197 guided by their reactivity mapping.Carbohydrate-Based Polymers for Immune ModulationTwo-step functionalization of oligosaccharides using glycosyl iodide and trimethylene oxide and its applications to multivalent glycoconjugates.Preparation and immunogenicity of gold glyco-nanoparticles as antipneumococcal vaccine model.Sugar-Protein Connectivity Impacts on the Immunogenicity of Site-Selective Salmonella O-Antigen Glycoconjugate Vaccines.Site-Specific Glycoconjugation of Protein via Bioorthogonal Tetrazine Cycloaddition with a Genetically Encoded trans-Cyclooctene or Bicyclononyne.Structural basis for fragmenting the exopolysaccharide of Acinetobacter baumannii by bacteriophage ΦAB6 tailspike protein.T cells control the generation of nanomolar-affinity anti-glycan antibodiesProtein micro- and nano-capsules for biomedical applications.Developments and recent advancements in the field of endogenous amino acid selective bond forming reactions for bioconjugation.Recent Developments in Synthetic Carbohydrate-Based Diagnostics, Vaccines, and Therapeutics.Towards the next generation of biomedicines by site-selective conjugation.Trends in therapeutic drug conjugates for bacterial diseases: a patent review.Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes.An Overview of Structural Features of Antibacterial Glycoconjugate Vaccines That Influence Their Immunogenicity.A semi-synthetic glycoconjugate vaccine candidate for carbapenem-resistant Klebsiella pneumoniae.Synthesis of the Heptasaccharide Repeating Unit of the Cell Wall O-Polysaccharide of Enterotoxigenic Escherichia coli O139.Site-Selective Modification of Proteins with Oxetanes.Site-specific chemical modification of antibody fragments using traceless cleavable linkers.Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease.One-Step Derivatization of Reducing Oligosaccharides for Rapid and Live-Cell-Compatible Chelation-Assisted CuAAC Conjugation.Chemical polyglycosylation and nanolitre detection enables single-molecule recapitulation of bacterial sugar export.Chemoenzymatic synthesis of heparan sulfate and heparin oligosaccharides and NMR analysis: paving the way to a diverse library for glycobiologists.A modular synthetic route to size-defined immunogenic Haemophilus influenzae b antigens is key to the identification of an octasaccharide lead vaccine candidate.Potential targets for next generation anti-microbial glycoconjugate vaccines.Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragment.A Semi-Synthetic Glycoconjugate Vaccine Candidate for Carbapenem-Resistant Klebsiella pneumoniae
P2860
Q28829950-9CB70C96-6985-4342-A6F7-99C9218558BFQ28830510-E2944CC1-2330-4C8B-944A-D3A7662DD6A7Q30238724-5AD757C2-D2B5-43BF-B743-96939F0B8E2FQ35116917-F215BE3D-FF28-4C16-9DC5-96F7EED9AF0BQ35212993-AE392C44-4950-4CF6-984E-E8B9091E3120Q35835615-E58774DA-57C6-42AC-9B35-C713AD2B3A32Q36202229-A0BF3042-F17A-447A-AF4B-ED239A7FB153Q36287530-AD00B2E4-76DD-45D0-B1E6-3967C73F0151Q36358330-EA389376-A6A1-4D1C-964D-97BF5ACBCE94Q37648715-CD2EDC3F-6A4A-440F-981D-5B1E3A8414EBQ37730648-37162597-ADB8-46F5-A947-A74284D07523Q38171252-FD3963B7-55DB-471D-BD78-AC345B93969AQ38497871-B4186400-73A7-4F27-A71D-A21A22F44562Q38533442-FF65CE8B-FC86-4B03-827E-970129B57DF6Q38706553-ADADB8B8-0C1B-4E3B-AEE5-90441CBB584EQ39003766-15579B5E-F06F-42C6-9191-B2FA8B847DECQ39012279-EF2086AB-D647-4825-946C-57D28C4747C3Q39093233-02AEE1A6-E9B8-4E21-9644-31A2237AAE98Q40090364-A89E7C8F-D69C-4224-9DDB-CB14243901CEQ42173577-29840605-2A55-4D83-B87C-9D05B7D114CBQ42260957-76E3DE88-A95E-4610-B4BA-4311204C0DE9Q44829143-7ADA33B1-7CC7-47CB-A2FC-AC269EA14797Q46027898-A2E23FF8-651A-450A-B686-E2334732B12AQ48245292-5B91D1F8-E53E-4951-9131-9364D6F70A70Q50859480-D814340D-71EA-436D-AC9B-6A5C7136762CQ52345400-455287FB-4E40-4BA5-A759-AF8E246D8B4BQ52804669-B6CC6D11-2A19-4FCE-ACE8-3C093B7091C5Q53701548-A98A347F-3B78-4E89-A514-E4F25ABF3EEEQ55322543-0ADF66F3-EB03-43BE-9D07-3D0B64A797B2Q57394794-3AEEBC29-D501-4A05-A854-41E2BE553830
P2860
Synthetically defined glycoprotein vaccines: current status and future directions.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Synthetically defined glycoprotein vaccines: current status and future directions.
@en
Synthetically defined glycoprotein vaccines: current status and future directions.
@nl
type
label
Synthetically defined glycoprotein vaccines: current status and future directions.
@en
Synthetically defined glycoprotein vaccines: current status and future directions.
@nl
prefLabel
Synthetically defined glycoprotein vaccines: current status and future directions.
@en
Synthetically defined glycoprotein vaccines: current status and future directions.
@nl
P2093
P2860
P356
P1433
P1476
Synthetically defined glycoprotein vaccines: current status and future directions
@en
P2093
Alberto Nilo
Bastien Castagner
Francesco Berti
Roberto Adamo
P2860
P304
P356
10.1039/C3SC50862E
P577
2013-05-16T00:00:00Z